Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits
Antonius Baartscheer, Cees A. Schumacher, Rob C. I. Wüst, et al.
Diabetologia (2016) Vol. 60, Iss. 3, pp. 568-573
Open Access | Times Cited: 552

Showing 1-25 of 552 citing articles:

Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association
Janani Rangaswami, Vivek Bhalla, John E. Blair, et al.
Circulation (2019) Vol. 139, Iss. 16
Open Access | Times Cited: 915
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Subodh Verma, John J.V. McMurray
Diabetologia (2018) Vol. 61, Iss. 10, pp. 2108-2117
Open Access | Times Cited: 792
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial
Silvio E. Inzucchi, Bernard Zinman, David Fitchett, et al.
Diabetes Care (2017) Vol. 41, Iss. 2, pp. 356-363
Open Access | Times Cited: 639
Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors
Gary D. Lopaschuk, Subodh Verma
JACC Basic to Translational Science (2020) Vol. 5, Iss. 6, pp. 632-644
Open Access | Times Cited: 618
SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control
Martín Cowie, Miles Fisher
Nature Reviews Cardiology (2020) Vol. 17, Iss. 12, pp. 761-772
Closed Access | Times Cited: 576
Metabolic remodelling in heart failure
Edoardo Bertero, Christoph Maack
Nature Reviews Cardiology (2018) Vol. 15, Iss. 8, pp. 457-470
Closed Access | Times Cited: 537
Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation
Laween Uthman, Antonius Baartscheer, Boris Bleijlevens, et al.
Diabetologia (2017) Vol. 61, Iss. 3, pp. 722-726
Open Access | Times Cited: 514
Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics
Carlos G. Santos‐Gallego, Juan Antonio Requena-Ibáñez, Rodolfo San Antonio, et al.
Journal of the American College of Cardiology (2019) Vol. 73, Iss. 15, pp. 1931-1944
Open Access | Times Cited: 511
Calcium Signaling and Reactive Oxygen Species in Mitochondria
Edoardo Bertero, Christoph Maack
Circulation Research (2018) Vol. 122, Iss. 10, pp. 1460-1478
Open Access | Times Cited: 484
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease
Christoph Wanner, John M. Lachin, Silvio E. Inzucchi, et al.
Circulation (2017) Vol. 137, Iss. 2, pp. 119-129
Open Access | Times Cited: 415
Sodium Glucose Cotransporter-2 Inhibition in Heart Failure
Yuliya Lytvyn, Petter Bjornstad, Jacob A. Udell, et al.
Circulation (2017) Vol. 136, Iss. 17, pp. 1643-1658
Open Access | Times Cited: 395
Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors
Ralph A. DeFronzo, William Reeves, Alaa S. Awad
Nature Reviews Nephrology (2021) Vol. 17, Iss. 5, pp. 319-334
Closed Access | Times Cited: 392
Renoprotective effects of sodium-glucose cotransporter-2 inhibitors
Hiddo J.L. Heerspink, Mikhail Kosiborod, Silvio E. Inzucchi, et al.
Kidney International (2018) Vol. 94, Iss. 1, pp. 26-39
Open Access | Times Cited: 324
Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure
Milton Packer, Stefan D. Anker, Javed Butler, et al.
JAMA Cardiology (2017) Vol. 2, Iss. 9, pp. 1025-1025
Closed Access | Times Cited: 320
2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
Sandeep R. Das, Brendan M. Everett, Kim K. Birtcher, et al.
Journal of the American College of Cardiology (2018) Vol. 72, Iss. 24, pp. 3200-3223
Open Access | Times Cited: 275
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
Vincenzo Quagliariello, Michelino De Laurentiis, Domenica Rea, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 269
Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling/Autophagy Hypothesis
Milton Packer
Circulation (2022) Vol. 146, Iss. 18, pp. 1383-1405
Open Access | Times Cited: 253
Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial
Milton Packer, Javed Butler, Gerasimos Filippatos, et al.
European Journal of Heart Failure (2019) Vol. 21, Iss. 10, pp. 1270-1278
Open Access | Times Cited: 251
SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects
Anastasios Tentolouris, Panayotis K. Vlachakis, Evangelia Tzeravini, et al.
International Journal of Environmental Research and Public Health (2019) Vol. 16, Iss. 16, pp. 2965-2965
Open Access | Times Cited: 245
Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation
Detmar Kolijn, Steffen Pabel, Yanna Tian, et al.
Cardiovascular Research (2020) Vol. 117, Iss. 2, pp. 495-507
Open Access | Times Cited: 237
Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats
Qingmiao Shao, Lei Meng, Sharen Lee, et al.
Cardiovascular Diabetology (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 234
From Systemic Inflammation to Myocardial Fibrosis
Walter J. Paulus, Michael R. Zile
Circulation Research (2021) Vol. 128, Iss. 10, pp. 1451-1467
Open Access | Times Cited: 214
Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association–European Society of Cardiology
Christoph Maack, Michael Lehrke, Johannes Backs, et al.
European Heart Journal (2018) Vol. 39, Iss. 48, pp. 4243-4254
Open Access | Times Cited: 209
Empagliflozin in acute myocardial infarction: the EMMY trial
Dirk von Lewinski, Ewald Kolesnik, Norbert J. Tripolt, et al.
European Heart Journal (2022) Vol. 43, Iss. 41, pp. 4421-4432
Open Access | Times Cited: 202
Activation and Inhibition of Sodium-Hydrogen Exchanger Is a Mechanism That Links the Pathophysiology and Treatment of Diabetes Mellitus With That of Heart Failure
Milton Packer
Circulation (2017) Vol. 136, Iss. 16, pp. 1548-1559
Closed Access | Times Cited: 201
Page 1 - Next Page

Scroll to top